TW473394B - Pharmaceutical composition comprising a smaller oral dosage form of valsartan - Google Patents
Pharmaceutical composition comprising a smaller oral dosage form of valsartan Download PDFInfo
- Publication number
- TW473394B TW473394B TW086113018A TW86113018A TW473394B TW 473394 B TW473394 B TW 473394B TW 086113018 A TW086113018 A TW 086113018A TW 86113018 A TW86113018 A TW 86113018A TW 473394 B TW473394 B TW 473394B
- Authority
- TW
- Taiwan
- Prior art keywords
- oral dosage
- valsartan
- pharmaceutical composition
- dosage form
- smaller oral
- Prior art date
Links
- 239000006186 oral dosage form Substances 0.000 title abstract 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 2
- 229960004699 valsartan Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000007787 solid Substances 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000006835 compression Effects 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 description 6
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940100629 oral lozenge Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Description
473394
ABCD 申請專利範圍 大小情況被壓縮。 17. 如申請專利範圍第13項之方法,其中顆粒係在25至65 仟牛頓之壓實力下形成。 18. —種固體口服錠劑’其係根據申請專利範圍第1 3項之方 法生產。 19. 如申請專利範圍第1或5項之固體口服錠劑,其係用於治 療高血壓(惡性高血壓、自發性高血壓、腎血管性高血 壓、糖尿病性高血壓、分離之心收縮壓性高血壓、或其 它第二型高血壓)、充血性心衰竭、心絞痛(穩定或不穩 定)、心肌梗塞、動脈硬化、糖尿病性腎病、糖尿病性 心肌病、腎功能不足、末梢血管病、左心室肥大、知覺 官能障礙(例如,阿耳滋海默氏病(Alzheimer,s)、中 風、頭痛及慢性心衰竭。 56569-1011029.doc 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公釐).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9613470.5A GB9613470D0 (en) | 1996-06-27 | 1996-06-27 | Small solid oral dosage form |
Publications (1)
Publication Number | Publication Date |
---|---|
TW473394B true TW473394B (en) | 2002-01-21 |
Family
ID=10795969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW086113018A TW473394B (en) | 1996-06-27 | 1997-09-09 | Pharmaceutical composition comprising a smaller oral dosage form of valsartan |
Country Status (33)
Country | Link |
---|---|
US (3) | US6294197B1 (zh) |
EP (7) | EP1410797B1 (zh) |
JP (5) | JP2000506540A (zh) |
KR (6) | KR101161283B1 (zh) |
CN (3) | CN1475207B (zh) |
AR (2) | AR008618A1 (zh) |
AT (3) | ATE276750T1 (zh) |
BR (1) | BR9709956A (zh) |
CA (2) | CA2673462C (zh) |
CO (1) | CO4870755A1 (zh) |
CY (1) | CY2553B1 (zh) |
CZ (1) | CZ296850B6 (zh) |
DE (3) | DE69738089T2 (zh) |
DK (3) | DK0914119T3 (zh) |
ES (3) | ES2335683T3 (zh) |
GB (1) | GB9613470D0 (zh) |
HK (2) | HK1019858A1 (zh) |
HU (1) | HU229134B1 (zh) |
ID (1) | ID17553A (zh) |
IL (2) | IL127564A0 (zh) |
MY (3) | MY156312A (zh) |
NO (2) | NO317181B1 (zh) |
NZ (2) | NZ333385A (zh) |
PE (1) | PE87498A1 (zh) |
PL (2) | PL188233B1 (zh) |
PT (3) | PT914119E (zh) |
RU (5) | RU2203054C2 (zh) |
SI (2) | SI0914119T1 (zh) |
SK (1) | SK285902B6 (zh) |
TR (1) | TR199802698T2 (zh) |
TW (1) | TW473394B (zh) |
WO (1) | WO1997049394A2 (zh) |
ZA (1) | ZA975673B (zh) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
US20030045561A1 (en) * | 2001-02-06 | 2003-03-06 | Smithkline Beecham Corporation | Method of treating isolated systolic hypertension |
WO1999044590A1 (en) * | 1998-03-04 | 1999-09-10 | Takeda Chemical Industries, Ltd. | Sustained-release preparation for aii antagonist, production and use thereof |
EP2263660B1 (en) * | 1998-05-18 | 2017-09-27 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
PT1096932E (pt) * | 1998-07-10 | 2007-09-21 | Novartis Pharma Ag | ''combinação anti-hipertensiva de valsartan e bloqueadores do canal de cálcio'' |
CA2622805C (en) * | 1998-12-23 | 2011-05-10 | Novartis Ag | Compressed tablets comprising valsartan |
PL197161B1 (pl) * | 1999-01-26 | 2008-03-31 | Novartis Ag | Zastosowanie antagonistów receptora angiotensyny II |
CN101011390A (zh) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
EP1210117A2 (en) * | 1999-08-24 | 2002-06-05 | Medicure International Inc. | Compositons for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds |
DE10066408B4 (de) * | 2000-03-24 | 2010-03-18 | 3M Espe Dental Ag | Verwendung feinkörniger Pulver für supragingivales Pulverstrahlen |
CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
AU2005200815B2 (en) * | 2000-06-22 | 2008-01-17 | Novartis Ag | Solid valsartan pharmaceutical compositions |
US20020132839A1 (en) * | 2000-06-22 | 2002-09-19 | Ganter Sabina Maria | Tablet formulations comprising valsartan |
CA2411882C (en) * | 2000-06-22 | 2011-09-06 | Novartis Ag | Solid valsartan pharmaceutical compositions |
PL205715B1 (pl) | 2000-07-19 | 2010-05-31 | Novartis Ag | Sól wapniowa walsartanu w postaci tetrahydratu, preparat farmaceutyczny zawierający tę sól, zastosowanie i sposób wytwarzania tej soli |
US20060089389A1 (en) | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
US20040219208A1 (en) * | 2001-08-03 | 2004-11-04 | Ryu Kawamura | Sustained-release medicines |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
DE10230272A1 (de) * | 2002-07-05 | 2004-01-22 | Solvay Pharmaceuticals Gmbh | AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen |
EP1382334A1 (en) * | 2002-07-11 | 2004-01-21 | Université de Picardie Jules Verne | Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke |
EP1950204A1 (en) | 2003-03-17 | 2008-07-30 | Teva Pharmaceutical Industries Ltd. | Amorphous form of valsartan |
US7199144B2 (en) * | 2003-04-21 | 2007-04-03 | Teva Pharmaceuticals Industries, Ltd. | Process for the preparation of valsartan and intermediates thereof |
ES2238022T3 (es) * | 2003-03-17 | 2008-11-01 | Teva Pharmaceutical Industries Ltd. | Poliformos de valsartan. |
EP1618097A1 (en) * | 2003-04-21 | 2006-01-25 | Teva Pharmaceutical Industries Ltd | Process for the preparation of valsartan |
EP1556363A2 (en) * | 2003-04-21 | 2005-07-27 | Teva Pharmaceutical Industries Limited | Process for the preparation of valsartan and intermediates thereof |
JP4505859B2 (ja) * | 2003-08-08 | 2010-07-21 | 味の素株式会社 | ナテグリニド含有製剤 |
EP1680095A2 (en) * | 2003-11-03 | 2006-07-19 | Zentiva, a.s. | Valsartan containing formulation |
GB0325605D0 (en) * | 2003-11-03 | 2003-12-10 | Novartis Ag | Combination of organic compounds |
JP2005187793A (ja) * | 2003-12-24 | 2005-07-14 | Rohm & Haas Electronic Materials Llc | 改良された接着剤 |
WO2005082329A2 (en) * | 2004-02-19 | 2005-09-09 | Ranbaxy Laboratories Limited | Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide |
WO2005089720A1 (en) * | 2004-03-10 | 2005-09-29 | Ranbaxy Laboratories Limited | Valsartan tablets and the process for the preparation thereof |
CA2573800A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries Ltd. | Preparation of olmesartan medoxomil |
LT1799196T (lt) | 2004-10-08 | 2016-09-12 | Forward Pharma A/S | Kontroliuojamo atpalaidavimo farmacinė kompozicija, apimanti fumaro rūgšties esterį |
JP4705108B2 (ja) * | 2004-10-15 | 2011-06-22 | ズートツッカー アクチェンゲゼルシャフト マンハイム/オクセンフルト | 改良されたパンコーティング法 |
EP1674080A1 (en) * | 2004-12-24 | 2006-06-28 | KRKA, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
CA2592091A1 (en) | 2004-12-24 | 2006-06-29 | Krka, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
FR2882260A1 (fr) * | 2005-02-21 | 2006-08-25 | Flamel Technologies Sa | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii |
AP2896A (en) * | 2005-05-31 | 2014-05-31 | Mylan Lab Inc | Compositions comprising nebivolol |
WO2007005967A2 (en) * | 2005-07-05 | 2007-01-11 | Teva Pharmaceutical Industries Ltd. | Process for preparing valsartan |
GB0513888D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
WO2007052307A2 (en) * | 2005-10-31 | 2007-05-10 | Lupin Limited | Stable solid oral dosage forms of valsartan |
RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
EP2007385A4 (en) * | 2006-03-23 | 2010-08-18 | Sinai School Medicine | CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER |
BRPI0712540A2 (pt) | 2006-06-06 | 2012-10-16 | Oleg Iliich Epshtein | agente medicinal para tratar adiposidade, diabetes, e doenças associadas com intoleráncia a glicose |
GB0612540D0 (en) | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
US20090304797A1 (en) * | 2006-06-23 | 2009-12-10 | Tarur Venkatasubramanian Radha | Process for the Preparation of Micronized Valsartan |
PE20081364A1 (es) * | 2006-09-04 | 2008-12-04 | Novartis Ag | Composicion farmaceutica que comprende valsartan |
EP1897537A1 (en) * | 2006-09-04 | 2008-03-12 | Novartis AG | Composition comprising an angiotensin II receptor antagonist |
WO2008054121A1 (en) * | 2006-10-30 | 2008-05-08 | Hanall Pharmaceutical Company. Ltd | Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers |
WO2008064338A2 (en) * | 2006-11-22 | 2008-05-29 | Rubicon Research Pvt. Ltd. | Valsartan formulation for pulsatile delivery |
WO2008120242A1 (en) * | 2007-03-29 | 2008-10-09 | Alembic Limited | Valsartan tablet formulations |
TR200703568A1 (tr) | 2007-05-24 | 2008-07-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Valsartan formülasyonları |
EP2175740B1 (en) * | 2007-07-31 | 2018-06-06 | Cargill, Incorporated | Direct compressible dextrose |
GB0715628D0 (en) * | 2007-08-10 | 2007-09-19 | Generics Uk Ltd | Solid valsartan composition |
CN101396366B (zh) * | 2007-09-25 | 2010-10-13 | 浙江华海药业股份有限公司 | 含缬沙坦的固体口服制剂及其制备方法 |
TW200924737A (en) * | 2007-09-28 | 2009-06-16 | Novartis Ag | Galenical formulations of organic compounds |
WO2009048848A1 (en) | 2007-10-09 | 2009-04-16 | Novartis Ag | Pharmaceutical formulation of valsartan |
AU2008324878B2 (en) | 2007-11-06 | 2013-04-18 | Novartis Ag | Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (ARB) and neutral endopeptidase (NEP) inhibitor |
EP2067470A1 (en) * | 2007-12-03 | 2009-06-10 | Laboratorios Lesvi, S.L. | Pharmaceutical compositions containing valsartan and process for its preparation |
US8785432B2 (en) * | 2007-12-31 | 2014-07-22 | Lupin Limited | Pharmaceutical compositions of amlodipine and valsartan |
EP2257288A1 (en) * | 2008-02-28 | 2010-12-08 | Novartis AG | Valsartan solid oral dosage forms and methods of making such formulations |
US20090226515A1 (en) * | 2008-03-04 | 2009-09-10 | Pharma Pass Ii Llc | Statin compositions |
US20090226516A1 (en) * | 2008-03-04 | 2009-09-10 | Pharma Pass Ii Llc | Sartan compositions |
CN102065847A (zh) * | 2008-04-29 | 2011-05-18 | 韩诺生物制约株式会社 | 含有血管紧张素-ⅱ受体阻断剂的药物制剂 |
AU2009257174A1 (en) * | 2008-06-09 | 2009-12-17 | Dimerix Bioscience Pty Ltd | Novel receptor hetero-dimers/-oligomers |
KR101033975B1 (ko) * | 2008-10-10 | 2011-05-11 | 이희엽 | 직접압축법을 이용한 발사르탄 함유 고형 경구 제형의 제조방법 및 이에 따라 제조된 고형 경구 제형 |
DE102008051783A1 (de) | 2008-10-17 | 2010-04-22 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Valsartan enthaltende Tablette |
US9387249B2 (en) | 2008-12-23 | 2016-07-12 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
WO2010104485A2 (en) | 2009-03-11 | 2010-09-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Valsartan formulations |
WO2011027021A1 (en) * | 2009-09-01 | 2011-03-10 | Orion Corporation | A method for the treatment of hypertension |
KR101084783B1 (ko) * | 2009-09-01 | 2011-11-22 | 삼성에스디아이 주식회사 | 이차 전지 및 그의 제조 방법 |
ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
CN101897675B (zh) * | 2010-02-10 | 2012-11-21 | 温士顿医药股份有限公司 | 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物 |
SI2536396T1 (sl) | 2010-02-16 | 2017-01-31 | KRKA, tovarna zdravil, d.d.,Novo mesto | Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan |
AR083417A1 (es) * | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
JP5882796B2 (ja) | 2011-03-31 | 2016-03-09 | キヤノン株式会社 | 振動体の駆動方法、振動装置、該振動装置を有する駆動装置、及び光学機器 |
GB201116993D0 (en) * | 2011-10-03 | 2011-11-16 | Ems Sa | Pharmaceutical compositions of antihypertensives |
WO2013098268A2 (en) | 2011-12-26 | 2013-07-04 | Novartis Ag | Tablets and dry-coated agents |
WO2013098578A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan hydrochlorothiazide |
WO2013098576A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan |
JP6018420B2 (ja) * | 2012-06-05 | 2016-11-02 | ニプロ株式会社 | アンジオテンシンii受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物 |
KR101944085B1 (ko) * | 2012-09-06 | 2019-01-30 | 한국콜마주식회사 | 발사르탄 함유 고형 경구제형 및 그 제조방법 |
JP2014062064A (ja) * | 2012-09-21 | 2014-04-10 | Ohara Yakuhin Kogyo Kk | バルサルタン含有錠剤の製造方法 |
JP6238831B2 (ja) * | 2014-04-25 | 2017-11-29 | 沢井製薬株式会社 | バルサルタン含有錠剤及びその製造方法 |
JP6141472B2 (ja) * | 2016-03-02 | 2017-06-07 | 大原薬品工業株式会社 | バルサルタン含有錠剤の製造方法 |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
WO2019241590A1 (en) | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition |
EP4295839A1 (en) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3200039A (en) | 1962-05-28 | 1965-08-10 | Pfizer & Co C | Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu |
GB1422176A (en) | 1973-05-05 | 1976-01-21 | Beecham Group Ltd | Pharmaceutical tablets |
AU528098B2 (en) | 1978-11-16 | 1983-04-14 | Beecham Group Plc | Analgesic tablet |
US4353887A (en) | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
US4238485A (en) * | 1979-10-29 | 1980-12-09 | Merck & Co., Inc. | Novel pharmaceutical compositions |
EP0070127A3 (en) | 1981-07-10 | 1983-08-17 | Beecham Group Plc | Tablets |
US4543359A (en) * | 1982-10-01 | 1985-09-24 | Eaton Laboratories, Inc. | Treating cardiac arrhythmias with dantrolene sodium |
HU187215B (en) * | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
US4609675A (en) * | 1984-08-17 | 1986-09-02 | The Upjohn Company | Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing |
US4743612A (en) * | 1986-10-17 | 1988-05-10 | Berlex Laboratories, Inc. | Prodrug derivatives of the cardiotonic agent 4-ethyl-1,3-dihydro-5-(4-(2-methyl-1H-imidazol-1-yl)benzoyl)-2H-imidazol-2-one, composition containing them, and method of using them to treat cardiac failure |
DE3705055A1 (de) * | 1987-02-18 | 1988-09-01 | Boehringer Ingelheim Kg | Verwendung von 2-(3-fluor-4-methylphenylimino)-imidazolidin zur behandlung der koronaren herzkrankheit |
JP2518854B2 (ja) * | 1987-06-19 | 1996-07-31 | 旭化成工業株式会社 | 固形製剤の製法 |
DE3739779A1 (de) * | 1987-11-24 | 1989-06-08 | Beiersdorf Ag | Pharmazeutische praeparate |
SE506179C2 (sv) * | 1989-01-23 | 1997-11-17 | Ciba Geigy Ag | Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum |
GB8909793D0 (en) | 1989-04-28 | 1989-06-14 | Beecham Group Plc | Pharmaceutical formulation |
DE19675036I2 (de) * | 1990-02-19 | 2004-10-21 | Novartis Ag | Acylverbindungen. |
AU8710691A (en) * | 1990-09-28 | 1992-04-28 | Mcneill-Ppc Inc. | Ibuprofen-diuretic combinations |
EP0553777B1 (en) * | 1992-01-29 | 2002-04-24 | Takeda Chemical Industries, Ltd. | Fast dissolving tablet and its production |
ZA931063B (en) | 1992-02-17 | 1993-09-23 | Ciba Geigy | Treatment of glaucoma. |
US5395627A (en) * | 1992-09-04 | 1995-03-07 | Akzo N.V. | Pharmaceutical granulate |
IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
WO1994009778A1 (en) | 1992-10-26 | 1994-05-11 | Merck & Co., Inc. | Combinations of angiotensin-ii receptor antagonists and diuretics |
AU5745394A (en) | 1992-12-30 | 1994-08-15 | Fmc Corporation | Readily available konjac glucomannan sustained release excipient |
JP3057471B2 (ja) * | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | アンジオテンシンii介在性諸疾患の予防または治療剤 |
US5464854A (en) | 1993-11-11 | 1995-11-07 | Depadova; Anathony S. | Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S. |
AT401871B (de) * | 1994-01-28 | 1996-12-27 | Gebro Broschek Gmbh | Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung |
JP3534130B2 (ja) * | 1994-03-01 | 2004-06-07 | 旭化成ケミカルズ株式会社 | 医薬品組成物 |
GB9404010D0 (en) * | 1994-03-02 | 1994-04-20 | Opt Tel Services Limited | Telephone dialling monitoring and route selecting apparatus |
PL316259A1 (en) * | 1994-03-17 | 1997-01-06 | Ciba Geigy Ag | Treatment of diabetic nephropathy with valsartan |
GB9408117D0 (en) | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
DE19502065C2 (de) * | 1995-01-14 | 1996-05-02 | Prophyta Biolog Pflanzenschutz | Pilzisolat mit fungizider Wirkung |
US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
FR2735365B1 (fr) * | 1995-06-14 | 1997-09-05 | Sanofi Sa | Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires |
GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
JP2011123241A (ja) * | 2009-12-10 | 2011-06-23 | Canon Inc | 撮影システム |
-
1996
- 1996-06-27 GB GBGB9613470.5A patent/GB9613470D0/en active Pending
-
1997
- 1997-06-14 MY MYPI20093392A patent/MY156312A/en unknown
- 1997-06-14 MY MYPI97002679A patent/MY123149A/en unknown
- 1997-06-14 MY MYPI20041863A patent/MY146868A/en unknown
- 1997-06-18 ES ES06126819T patent/ES2335683T3/es not_active Expired - Lifetime
- 1997-06-18 EP EP03027840A patent/EP1410797B1/en not_active Revoked
- 1997-06-18 EP EP09001681A patent/EP2055301A1/en not_active Withdrawn
- 1997-06-18 AT AT97929209T patent/ATE276750T1/de active
- 1997-06-18 AT AT06126819T patent/ATE446749T1/de active
- 1997-06-18 KR KR1020097017936A patent/KR101161283B1/ko not_active IP Right Cessation
- 1997-06-18 SI SI9730686T patent/SI0914119T1/xx unknown
- 1997-06-18 PT PT97929209T patent/PT914119E/pt unknown
- 1997-06-18 KR KR1020067011260A patent/KR20060079260A/ko not_active Application Discontinuation
- 1997-06-18 US US09/202,805 patent/US6294197B1/en not_active Expired - Lifetime
- 1997-06-18 IL IL12756497A patent/IL127564A0/xx unknown
- 1997-06-18 EP EP06126829A patent/EP1774967A1/en not_active Withdrawn
- 1997-06-18 SI SI9730773T patent/SI1410797T1/sl unknown
- 1997-06-18 EP EP06126838A patent/EP1767207A3/en not_active Withdrawn
- 1997-06-18 PL PL97330709A patent/PL188233B1/pl not_active IP Right Cessation
- 1997-06-18 ES ES97929209T patent/ES2231873T3/es not_active Expired - Lifetime
- 1997-06-18 KR KR1020117011286A patent/KR101208430B1/ko not_active IP Right Cessation
- 1997-06-18 PT PT03027840T patent/PT1410797E/pt unknown
- 1997-06-18 CN CN031466788A patent/CN1475207B/zh not_active Expired - Lifetime
- 1997-06-18 ES ES03027840T patent/ES2290400T3/es not_active Expired - Lifetime
- 1997-06-18 DE DE69738089T patent/DE69738089T2/de not_active Expired - Lifetime
- 1997-06-18 RU RU99101056/14A patent/RU2203054C2/ru active IP Right Maintenance
- 1997-06-18 BR BR9709956A patent/BR9709956A/pt not_active Application Discontinuation
- 1997-06-18 TR TR1998/02698T patent/TR199802698T2/xx unknown
- 1997-06-18 JP JP10502269A patent/JP2000506540A/ja active Pending
- 1997-06-18 EP EP97929209A patent/EP0914119B1/en not_active Expired - Lifetime
- 1997-06-18 DE DE69730834T patent/DE69730834T2/de not_active Expired - Lifetime
- 1997-06-18 EP EP06126819A patent/EP1767206B1/en not_active Revoked
- 1997-06-18 CZ CZ0426998A patent/CZ296850B6/cs not_active IP Right Cessation
- 1997-06-18 KR KR1020087000538A patent/KR20080014149A/ko active Search and Examination
- 1997-06-18 PT PT06126819T patent/PT1767206E/pt unknown
- 1997-06-18 CA CA2673462A patent/CA2673462C/en not_active Expired - Fee Related
- 1997-06-18 AT AT03027840T patent/ATE371449T1/de active
- 1997-06-18 KR KR1020057015071A patent/KR100792389B1/ko not_active IP Right Cessation
- 1997-06-18 RU RU99101056/63D patent/RU2294743C2/ru not_active IP Right Cessation
- 1997-06-18 CN CN2006100999105A patent/CN1951372B/zh not_active Expired - Lifetime
- 1997-06-18 DK DK97929209T patent/DK0914119T3/da active
- 1997-06-18 NZ NZ333385A patent/NZ333385A/xx not_active IP Right Cessation
- 1997-06-18 PL PL97363524A patent/PL188271B1/pl unknown
- 1997-06-18 CN CNB971958912A patent/CN1133427C/zh not_active Expired - Lifetime
- 1997-06-18 EP EP06126834A patent/EP1776953A1/en not_active Withdrawn
- 1997-06-18 SK SK1784-98A patent/SK285902B6/sk not_active IP Right Cessation
- 1997-06-18 DK DK06126819.9T patent/DK1767206T3/da active
- 1997-06-18 DK DK03027840T patent/DK1410797T3/da active
- 1997-06-18 KR KR1019980710521A patent/KR100618038B1/ko not_active IP Right Cessation
- 1997-06-18 HU HU0203374A patent/HU229134B1/hu not_active IP Right Cessation
- 1997-06-18 WO PCT/EP1997/003172 patent/WO1997049394A2/en active Search and Examination
- 1997-06-18 DE DE69739642T patent/DE69739642D1/de not_active Expired - Lifetime
- 1997-06-18 CA CA002259148A patent/CA2259148C/en not_active Expired - Fee Related
- 1997-06-23 CO CO97034775A patent/CO4870755A1/es unknown
- 1997-06-24 PE PE1997000539A patent/PE87498A1/es not_active IP Right Cessation
- 1997-06-25 AR ARP970102790A patent/AR008618A1/es active IP Right Grant
- 1997-06-26 ID IDP972207A patent/ID17553A/id unknown
- 1997-06-26 ZA ZA9705673A patent/ZA975673B/xx unknown
- 1997-09-09 TW TW086113018A patent/TW473394B/zh not_active IP Right Cessation
-
1998
- 1998-12-22 NO NO19986056A patent/NO317181B1/no not_active IP Right Cessation
-
1999
- 1999-11-09 HK HK99105148A patent/HK1019858A1/xx not_active IP Right Cessation
-
2001
- 2001-08-01 US US09/920,159 patent/US6485745B1/en not_active Expired - Fee Related
-
2002
- 2002-09-20 US US10/251,009 patent/US6858228B2/en not_active Expired - Fee Related
-
2003
- 2003-01-23 JP JP2003014987A patent/JP2003231634A/ja not_active Withdrawn
- 2003-02-21 NZ NZ524346A patent/NZ524346A/en not_active IP Right Cessation
-
2004
- 2004-03-26 NO NO20041287A patent/NO331739B1/no not_active IP Right Cessation
- 2004-05-25 HK HK04103718.1A patent/HK1060700A1/xx not_active IP Right Cessation
-
2006
- 2006-03-21 CY CY0600007A patent/CY2553B1/xx unknown
-
2007
- 2007-01-10 RU RU2007100200/15A patent/RU2453306C2/ru not_active IP Right Cessation
- 2007-02-06 AR ARP070100474A patent/AR059324A2/es not_active Application Discontinuation
- 2007-06-28 JP JP2007170267A patent/JP4969338B2/ja not_active Expired - Lifetime
-
2008
- 2008-11-17 IL IL195339A patent/IL195339A0/en unknown
-
2009
- 2009-04-27 RU RU2009115778/15A patent/RU2009115778A/ru unknown
-
2011
- 2011-12-09 JP JP2011270429A patent/JP2012051948A/ja not_active Withdrawn
-
2013
- 2013-03-26 RU RU2013113610/15A patent/RU2013113610A/ru not_active Application Discontinuation
- 2013-10-25 JP JP2013221985A patent/JP2014012747A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW473394B (en) | Pharmaceutical composition comprising a smaller oral dosage form of valsartan | |
IL190802A0 (en) | Therapeutic combination of amlodipine and benazepril/benazeprilat | |
EP1138320A3 (de) | Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung | |
MXPA04005105A (es) | Formulaciones de acitromicina directamente compresibles. | |
CY1116770T1 (el) | Συνδυασμενη χρηση βαλσαρτανης και παρεμποδιστων διαυλων ασβεστιου για θεραπευτικους σκοπους | |
IT1256282B (it) | Composizione farmaceutica che comprende una particolare forma fisica di un derivato di un'ammide eterociclica | |
AR053440A2 (es) | Uso de una forma de dosificacion farmaceutica de liberacion sostenida para la manufactura de un medicamento, dicha forma de dosificacion farmaceutica y una tableta comprimida | |
BR9808429A (pt) | Composição farmacêutica e processo para a sua preparação. | |
ATE333265T1 (de) | Oral anzuwendende schnell zerfallende feste darreichungsformen | |
BG104075A (en) | Combined treatment including atorvastatin and an antihypertonic form | |
JP2003530346A5 (zh) | ||
MY138846A (en) | Sustained-release tablet composition of pramipexole | |
CA2382387A1 (en) | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure | |
AU2001285768B2 (en) | Solid valsartan pharmaceutical compositions | |
CR7074A (es) | Derivados de mercaptoacetylamida y proceso para su preparacion y uso | |
AU2006249254A1 (en) | Combinations comprising COX-2 inhibitors and aspirin | |
NO20023551L (no) | Ibuprofen-inneholdende aktivt middel-preparat | |
KR102369607B1 (ko) | 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물 | |
JP2004527489A5 (zh) | ||
TNSN07166A1 (en) | Composition comprising vlp and amyloid-beta peptide | |
CY1106129T1 (el) | Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος | |
ES2122387T3 (es) | Procedimiento para la preparacion de la forma 1 del clorhidrato de ranitidina. | |
MD1854G2 (ro) | Metodă de tratament în insuficienţa cardiacă congestivă | |
IT1317885B1 (it) | Uso di fibrati per la preparazione di un medicamento utile neltrattamento dell'insufficienza cardiaca congestizia. | |
TH31641A (th) | ยาให้ทางปากที่อยู่ในรูปของของแข็ง |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |